Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced / metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Mdm2 Amplified, Tp53 Wild-type Biliary Tract Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Or Other Selected Solid Tumours
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Biliary tract adenocarcinoma, pancreatic ductal adenocarcinoma, lung adenocarcinoma, or urothelial bladder cancer
    2. Be able to provide samples of tumor tissue preserved in a specific way (using formalin and paraffin)
    3. Adequate organ function

You may not be eligible for this study if the following are true:

    1. Currently experiencing active bleeding, have a significant risk of hemorrhage (such as a history of severe gastrointestinal bleeding or a previous hemorrhagic stroke), or have a current bleeding disorder
    2. A major surgery within four weeks before starting the trial treatment, or if you are planning to have a major surgery within six months after the initial screening
    3. Currently undergoing treatment for brain metastases (cancer that has spread to the brain) or leptomeningeal disease (cancer that has spread to the membranes surrounding the brain and spinal cord)



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.